TSHA - What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? | Benzinga
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 under the Option Agreement between Astellas and Taysha Gene Therapies Inc (NASDAQ: TSHA).
In October 2022, Taysha gave Astellas an option to license its gene therapy candidate TSHA-120 in the neurodegenerative disorder giant axonal neuropathy (GAN) as part of a two-asset agreement.
Astellas paid $20 million upfront, invested $30 million in Taysha to ...